THURSDAY, Aug. 4, 2022 (HealthDay News)
“While hearing loss associated with the administration of platinum drugs was reported in adults with testicular and head and neck cancer, our study is the first to demonstrate that hearing loss and tinnitus are highly prevalent problems in survivors of the four most common types of cancer,” said first author Dr. Steven Cheung. He is a professor of otolaryngology—head and neck surgery at the University of California, San Francisco (UCSF).
“These high rates of hearing loss and tinnitus occur not only with platinum drugs, but with another class of chemotherapy drugs called taxanes,” Cheung said in a university news release. “Given that platinum- and taxane-containing chemotherapy regimens are the ones most commonly used to treat the majority of cancers, these findings have huge implications for clinicians who treat cancer patients, as well as for cancer survivors.”
Children who receive chemotherapy routinely undergo hearing tests, but adults don’t, the study authors said.
The study, published online July 27 in BMJ Supportive & Palliative Care, included 273 people (average age, 61) who had completed treatment about five years earlier for breast, gastrointestinal, lung and gynecologic cancers.
Participants who had hearing loss reported moderate to severe impairment during routine activity, such as listening to television or radio, talking with family members and friends, or having a conversation in restaurants.
While about 31% of participants denied having hearing loss, audiometry found impairments, according to the report.
“While individuals often underestimate hearing problems, our findings point to the need for cancer survivors to have their hearing tested,” said senior author Christine Miaskowski of UCSF’s School of Nursing and Helen Diller Family Comprehensive Cancer Center.
“Though the type of hearing loss that occurs with platinum and taxane drugs is permanent, patients’ hearing can be improved with the use of a hearing aid,” Miaskowski said. “Only 17% of the survivors in our study were using a hearing aid, which suggests that clinicians need to refer survivors for a hearing test on a routine basis.”
Evaluations of hearing loss and tinnitus should be done before, during and after chemotherapy, the study authors advised. Routine screening and follow-up should be done by hearing professionals, and plans for managing tinnitus require consultation with specialists.
The U.S. National Institute on Aging has more on hearing loss in adults.
SOURCE: University of California, San Francisco, news release, July 27, 2022
By Cara Murez HealthDay Reporter
Copyright © 2021 HealthDay. All rights reserved.